Evaluation of Local Co-administration of Autologous ADIpose Derived Stromal Vascular Fraction With Microfat for Refractory Perianal CROHN's Fistulas. (ADICROHN2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04010526 |
|
Recruitment Status :
Not yet recruiting
First Posted : July 8, 2019
Last Update Posted : March 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Autologous ADSVF constitutes an innovative therapeutic strategy that concentrates various types of regenerative stem cells and paracrine factors able to promote angiogenesis and tissue repair. Together with the ease of collection from a minimally manipulated lipoaspirate, the unique properties of ADSVF offer new opportunities for fistulas' healing in patients with CD. The use of ADSVF is currently developed in many clinical fields based on safety and efficacy data.
Our ADICROHN pilot study evaluating safety and tolerance of local administration of autologous ADSVF with microfat in CD patients with complex perianal fistula refractory to conventional medical and surgical therapy showed that this novel therapeutic approach appears feasible and safe.
However the therapeutic potential of local this combined treatment in healing refractory perianal Crohn's fistulas still remains to be demonstrated.
The main objective of this study is to assess the efficacy of local injection of autologous ADSVF and microfat versus placebo for the treatment of complex refractory perianal Crohn's fistulas at week 24.
The efficacy will be assessed on clinical assessment of closure of all the external openings that were drained at baseline, and MRI confirmation of absence of collections > 2 cm of the treated perianal fistulas at week 24.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Crohn Disease | Combination Product: local co-administration of autologous ADIpose Other: placebo | Phase 2 |
Autologous ADSVF constitutes an innovative therapeutic strategy that concentrates various types of regenerative stem cells and paracrine factors able to promote angiogenesis and tissue repair. Together with the ease of collection from a minimally manipulated lipoaspirate, the unique properties of ADSVF offer new opportunities for fistulas' healing in patients with CD. The use of ADSVF is currently developed in many clinical fields based on safety and efficacy data.
Our ADICROHN pilot study evaluating safety and tolerance of local administration of autologous ADSVF with microfat in CD patients with complex perianal fistula refractory to conventional medical and surgical therapy showed that this novel therapeutic approach appears feasible and safe.
However the therapeutic potential of local this combined treatment in healing refractory perianal Crohn's fistulas still remains to be demonstrated.
B. Primary objective/endpoint The main objective of this study is to assess the efficacy of local injection of autologous ADSVF and microfat versus placebo for the treatment of complex refractory perianal Crohn's fistulas at week 24 (W24), The efficacy will be assessed on clinical assessment of closure (despite gentle finger compression) of all the external openings that were drained at baseline, and MRI confirmation of absence of collections > 2 cm of the treated perianal fistulas at week 24.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 84 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Other |
| Official Title: | Double-blind Randomised Placebo Controlled Study Evaluating Local Co-administration of Autologous ADIpose Derived Stromal Vascular Fraction With Microfat for Refractory Perianal CROHN's Fistulas. |
| Estimated Study Start Date : | March 2020 |
| Estimated Primary Completion Date : | July 2022 |
| Estimated Study Completion Date : | October 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: treatment
CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
|
Combination Product: local co-administration of autologous ADIpose
local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging. |
|
Placebo Comparator: placebo
CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
|
Other: placebo
local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV |
- clinically evaluated [ Time Frame: 24 weeks (w) ]number of fistula closure
- Magnetic resonance imaging (MRI) [ Time Frame: weeks 24 ]confirmation of absence of collections > 2 cm of the treated perianal fistulas
- Magnetic resonance imaging (MRI) [ Time Frame: weeks 52 ]confirmation of absence of collections > 2 cm of the treated perianal fistulas
- a complete cessation of suppuration [ Time Frame: weeks4, weeks12, weeks24, weeks52 ]
- closure of all the external openings [ Time Frame: weeks4, weeks12 ]
- Index PDAI (Perianal Disease Activity ) [ Time Frame: weeks4, weeks12, weeks24 and weeks52 ]
- improvement of Quality of Life Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (QoL) [ Time Frame: weeks4, weeks12, weeks24 and weeks52 ]
- Crohn's Disease Activity Index (CDAI) [ Time Frame: weeks4, weeks12, weeks24 and weeks52 ]
- Reduction of anal incontinence severity (Wexner score) [ Time Frame: weeks4, weeks12, weeks24 and weeks52 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent
- Patients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria
- Presence of refractory complex perianal fistulas assessed by clinical assessment during examination under anaesthesia (preparation treatment) and MRI.
- Non-active or mildly active luminal CD defined by a CDAI ≤ 220
- Patients of either sex aged 18 years or older
- Good general state of health according to clinical history and a physical examination
- For women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin [hCG]). Both men and women should use appropriate birth control methods defined by the investigator.
Exclusion Criteria:
- Presence of dominant luminal active Crohn's disease requiring immediate therapy
- CDAI > 220
- Patient naïve to specific treatment for perianal fistulising Crohn's disease
- Presence of an abscess or collections > 2 cm, unless resolved in the preparation procedure
- Rectal and/or anal stenosis if this means a limitation for any surgical procedure
- Patient with ongoing steroid treatment or treated with steroids in the last 4 weeks
- Malignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma
- Current or recent history of abnormal, severe, progressive, uncontrolled infectious, hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease
- Congenital or acquired immunodeficiencies
- Contraindication to local anaesthetics or gadolinium (MRI contrast)
- Contraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia)
- Pregnant or breastfeeding women
- Contraindication to the anaesthetic or surgical procedure
- BMI < 18 to insure adequate abdominal or other subcutaneous adipose tissue accessible by lipoharvest
- Any active viral infection follows: HIV, HTLV I et II, VHB, VHC and Syphillis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04010526
| Contact: JEAN CHARLES GRIMAUD, MD | +33491368739 | Jean-charles.GRIMAUD@ap-hm.fr |
| France | |
| Assistance Publique Des Hopitaux de Marseille | |
| Marseille, Paca, France, 13354 | |
| Contact: JEAN CHARLES GRIMAUD, MD +33491368739 Jean-charles.GRIMAUD@ap-hm.fr | |
| Study Director: | EMILIE GARRIDO PRADALIE | APHM |
| Responsible Party: | Assistance Publique Hopitaux De Marseille |
| ClinicalTrials.gov Identifier: | NCT04010526 |
| Other Study ID Numbers: |
RCAPHM18_0013 |
| First Posted: | July 8, 2019 Key Record Dates |
| Last Update Posted: | March 18, 2020 |
| Last Verified: | March 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Crohn Disease Fistula Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases Pathological Conditions, Anatomical |